These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Vorinostat Combined with High-Dose Gemcitabine, Busulfan, and Melphalan with Autologous Stem Cell Transplantation in Patients with Refractory Lymphomas. Nieto Y; Valdez BC; Thall PF; Ahmed S; Jones RB; Hosing C; Popat U; Shpall EJ; Qazilbash M; Gulbis A; Anderlini P; Alousi A; Shah N; Bashir Q; Liu Y; Oki Y; Hagemeister F; Fanale M; Dabaja B; Pinnix C; Champlin R; Andersson BS Biol Blood Marrow Transplant; 2015 Nov; 21(11):1914-20. PubMed ID: 26071868 [TBL] [Abstract][Full Text] [Related]
10. Rationale for poly(ADP-ribose) polymerase (PARP) inhibitors in combination therapy with camptothecins or temozolomide based on PARP trapping versus catalytic inhibition. Murai J; Zhang Y; Morris J; Ji J; Takeda S; Doroshow JH; Pommier Y J Pharmacol Exp Ther; 2014 Jun; 349(3):408-16. PubMed ID: 24650937 [TBL] [Abstract][Full Text] [Related]
11. Combining inotuzumab ozogamicin with PARP inhibitors olaparib and talazoparib exerts synergistic cytotoxicity in acute lymphoblastic leukemia by inhibiting DNA strand break repair. Ida N; Okura M; Tanaka S; Hosono N; Yamauchi T Oncol Rep; 2024 Jul; 52(1):. PubMed ID: 38785163 [TBL] [Abstract][Full Text] [Related]
12. Synergistic Cytotoxic Effect of Busulfan and the PARP Inhibitor Veliparib in Myeloproliferative Neoplasms. Patel PR; Senyuk V; Rodriguez NS; Oh AL; Bonetti E; Mahmud D; Barosi G; Mahmud N; Rondelli D Biol Blood Marrow Transplant; 2019 May; 25(5):855-860. PubMed ID: 30615982 [TBL] [Abstract][Full Text] [Related]
13. PARP inhibitors synergize with gemcitabine by potentiating DNA damage in non-small-cell lung cancer. Jiang Y; Dai H; Li Y; Yin J; Guo S; Lin SY; McGrail DJ Int J Cancer; 2019 Mar; 144(5):1092-1103. PubMed ID: 30152517 [TBL] [Abstract][Full Text] [Related]
14. [Effect and Mechanism of Radiosensitization of Poly (ADP-Ribose) Polymerase Inhibitor n Lewis Cells and Xenografts]. Wang W; Duan B; Zeng L Zhongguo Fei Ai Za Zhi; 2016 Jan; 19(1):16-23. PubMed ID: 26805733 [TBL] [Abstract][Full Text] [Related]
15. A phase I combination study of olaparib with cisplatin and gemcitabine in adults with solid tumors. Rajan A; Carter CA; Kelly RJ; Gutierrez M; Kummar S; Szabo E; Yancey MA; Ji J; Mannargudi B; Woo S; Spencer S; Figg WD; Giaccone G Clin Cancer Res; 2012 Apr; 18(8):2344-51. PubMed ID: 22371451 [TBL] [Abstract][Full Text] [Related]
16. Combination of talaporfin photodynamic therapy and Poly (ADP-Ribose) polymerase (PARP) inhibitor in gastric cancer. Tanaka M; Sasaki M; Suzuki T; Nishie H; Kataoka H Biochem Biophys Res Commun; 2021 Feb; 539():1-7. PubMed ID: 33388624 [TBL] [Abstract][Full Text] [Related]
17. Mechanistic studies on the synergistic cytotoxicity of the nucleoside analogs gemcitabine and clofarabine in multiple myeloma: relevance of p53 and its clinical implications. Valdez BC; Wang G; Murray D; Nieto Y; Li Y; Shah J; Turturro F; Wang M; Weber DM; Champlin RE; Qazilbash MH; Andersson BS Exp Hematol; 2013 Aug; 41(8):719-30. PubMed ID: 23648290 [TBL] [Abstract][Full Text] [Related]
18. PARP inhibitor Olaparib Enhances the Apoptotic Potentiality of Curcumin by Increasing the DNA Damage in Oral Cancer Cells through Inhibition of BER Cascade. Molla S; Hembram KC; Chatterjee S; Nayak D; Sethy C; Pradhan R; Kundu CN Pathol Oncol Res; 2020 Oct; 26(4):2091-2103. PubMed ID: 31768967 [TBL] [Abstract][Full Text] [Related]
19. HDAC inhibitors suppress protein poly(ADP-ribosyl)ation and DNA repair protein levels and phosphorylation status in hematologic cancer cells: implications for their use in combination with PARP inhibitors and chemotherapeutic drugs. Valdez BC; Nieto Y; Yuan B; Murray D; Andersson BS Oncotarget; 2022 Oct; 13():1122-1135. PubMed ID: 36243940 [TBL] [Abstract][Full Text] [Related]
20. Epigenetic modifiers enhance the synergistic cytotoxicity of combined nucleoside analog-DNA alkylating agents in lymphoma cell lines. Valdez BC; Nieto Y; Murray D; Li Y; Wang G; Champlin RE; Andersson BS Exp Hematol; 2012 Oct; 40(10):800-10. PubMed ID: 22687754 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]